Compare ATNI & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATNI | SIGA |
|---|---|---|
| Founded | 1987 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 392.6M | 341.0M |
| IPO Year | 1994 | 2016 |
| Metric | ATNI | SIGA |
|---|---|---|
| Price | $27.23 | $4.62 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 55.6K | ★ 531.2K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | 4.03% | ★ 13.24% |
| EPS Growth | ★ 34.29 | N/A |
| EPS | N/A | ★ 0.32 |
| Revenue | ★ $727,975,000.00 | N/A |
| Revenue This Year | $3.12 | N/A |
| Revenue Next Year | $1.10 | $224.81 |
| P/E Ratio | ★ N/A | $14.47 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.76 | $4.29 |
| 52 Week High | $30.45 | $9.62 |
| Indicator | ATNI | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 47.39 | 43.32 |
| Support Level | $25.13 | $4.29 |
| Resistance Level | $29.24 | $4.80 |
| Average True Range (ATR) | 1.03 | 0.13 |
| MACD | -0.10 | 0.05 |
| Stochastic Oscillator | 31.91 | 52.00 |
ATN International Inc is a telecommunications and utilities company. The company provides digital infrastructure and communications services with a focus on rural and remote markets in the United States, and internationally, including Bermuda and the Caribbean region. Its operating segments comprise U.S. Telecom and International Telecom. The company earns revenue from its International telecommunication segment.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.